Brief: Pharma Mar and Boryung Pharm sign licensing deal for Aplidin in South Korea

Boryung

04/10/2016 08:46

Oct 4 (Reuters) - Pharma Mar SA  PHMR.MC : 
    * Pharma Mar and Boryung Pharm have signed a licensing 
agreement to commercialize the marine-derived anticancer drug 
Aplidin (plitidepsin) in South Korea  
    * Under terms of the deal, Pharma Mar will receive an 
upfront payment, royalties and additional remunerations upon 
achieving regulatory milestones with Aplidin 
    * PharmaMar will retain exclusive production rights and will 
supply the finished product to Boryung Pharm for commercial use 
 
 
Source text: http://bit.ly/2dNiRP8 
     
Further company coverage:  PHMR.MC  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))